Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

September 24, 2025

atai Wins $11.4M NIDA Grant to Develop Non-Hallucinogenic Psychedelics for OUD • Australia’s Largest Private Health Insurer Funds Psilocybin for Treatment-Resistant Depression Pilot • Osmind and Bendable Share Real-World Outcomes from 88 Psilocybin Clients • Psychedelic Pipeline Bullseye Chart Update Log • Pennsylvania Lawmakers Talk Psychedelics in Hearing on Treatment-Resistant Depression • Reunion Upsizes Series A to $133M Following Phase 2 Success • Virtual Ketamine Startup Noma Therapy to Wind Down Operations • Feilding Commission Launches to Develop UK Framework for Psychedelic-Assisted Therapy • Neurocrine’s Osavampator Prints Positive Phase 2 Results • atai and Beckley Share Positive Open-Label Two-Dose Data • and more…

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

September 22, 2025

MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here, we speak to researchers about the trial, diving deeper into topics including the dose-response effect, the candidate’s safety profile, and non-pharmacological elements of the study, including the company’s decision not to record any of the sessions in its Phase 2b or Phase 3 studies.

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more